Amit Sanyal, MD: A Clinician’s Perspective

First International Summit on Interventional Pharmacoeconomics

Welcome and Introduction to Vi3C

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Deborah Collyar: What's In It for Patients?

The Interventional Pharmacoeconomic Toolbox Panel Discussion

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Jan

Today In Oncology

Amit Sanyal, MD: A Clinician’s Perspective

Related Videos

Welcome and Introduction to Vi3C

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Collyar: What's In It for Patients?

The Interventional Pharmacoeconomic Toolbox Panel Discussion

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

ASTRO Relaunches Research Foundation Under a Single, Focused Identity

Determining the Optimal Duration of Androgen-Deprivation Therapy Added to Definitive Radiotherapy in Localized Prostate Cancer

Addition of Tafasitamab to Lenalidomide Plus Rituximab in Relapsed or Refractory Follicular Lymphoma

A Novel Paradigm in Acute Kidney Injury Congestive Nephropathy in RCC With IVC Thrombus

County-Level Obesity Prevalence May Predict Obesity-Related Cancer Rates in Young Adults